Likewise, Weinberg (25) states that due to the current situation, nurses have to "respond to the demands of patients in spite of the overload represented by the requirements of their work, even sacrificing their own personal care and the time required to take care of the small details that
humanized care includes" and "they are not permitted to comply with patient-care activities due to having to meet institutional requirements and from other professionals and, due to this, contact with patients is limited to the basic or necessary, that is, to performing procedures on the physical plane".
The new topical PrEP study by Denton and coauthors in
humanized BLT mice reproduced the CAPRISA experimental design with tenofovir.
XmAb[R]5574 is a
humanized monoclonal antibody that targets the antigen CD19 for treatment of B cell malignancies and autoimmune diseases.
Sullivan, president and CEO of Immunomedics, said that the
humanized anti-CD19 antibody was designed using the same human antibody backbone as veltuzumab and epratuzumab, which demonstrated strong safety characteristics in many trials in autoimmune and oncology diseases.
Earlier this year, Celltech announced that it has entered into a collaboration agreement with Pharmacia for the development and commercialization of its anti-tumor necrosis factor-alpha
humanized antibody fragment, known as CDP 870, currently undergoing Phase II trials in patients with active rheumatoid arthritis.
SGN-40 is a
humanized monoclonal antibody that targets the CD40 antigen, which is highly expressed on most B lineage hematologic malignancies including non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia.
Protein Design has granted licenses under its antibody humanization patents for each of the three currently marketed
humanized antibodies.
In the area of HIV infection, the Company is developing the viral-entry inhibitor, PRO 140, a
humanized monoclonal antibody targeting the HIV coreceptor CCR5 (in phase 1b studies).
Overall, Protein Design has entered into agreements with numerous pharmaceutical and biotechnology companies for exclusive or non-exclusive rights under its antibody humanization patents covering nearly 40
humanized antibodies, over half of which are in clinical development.
Seattle Genetics and its collaborators presented preclinical data on SGN-70, a
humanized monoclonal antibody that targets the CD70 antigen, which is expressed in many types of hematologic malignancies.
Protein Design has a strong intellectual property position in the antibody field, with issued patents in the United States, Europe and Japan that we believe cover most
humanized antibodies," said Robert L.
SGN-70, a
humanized anti-CD70 antibody, targets CD70-expressing hematologic tumors Poster session on Sunday, December 10, 2006; 9:00am - 8:00pm ET Abstract: #2492 -- Targeted depletion and inhibition of activated T lymphocytes with SGN-70, a
humanized antibody specific for the activation of antigen CD70 Poster session on Saturday, December 9, 2006; 9:00am - 7:30pm ET Abstract: #1728 -- Preclinical in vitro and in vivo evidence support a therapeutic role for the CD70 directed monoclonal antibody (SGN-70) in Waldenstrom's macroglobulinemia (WM) Poster session on Sunday, December 10, 2006; 9:00am - 8:00pm ET Abstract: #2490
